News
Amgen adds BiTE to its cancer range as FDA clears Imdelltra
Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority revie
